Literature DB >> 2985170

Prevalence of antibody to human T lymphotropic virus type III by risk group and area, United Kingdom 1978-84.

P P Mortimer, W J Jesson, E M Vandervelde, M S Pereira.   

Abstract

Antibody to human T lymphotropic virus type III (anti-HTLV-III) was sought in 2150 patients in three groups at risk with a radioimmunoassay and an immunofluorescence test. Results by the two methods were closely concordant. Anti-HTLV-III was already present in some British homosexuals in 1980 and in some British haemophiliacs in 1981, and since then its prevalence has increased. Of homosexual patients needing laboratory tests for hepatitis B virus infection in 1984, 34% of 282 in London and 5% of 955 in five centres outside London were positive for anti-HTLV-III. Of haemophiliacs sampled in 1984, 38% of 81 were anti-HTLV-III positive. Most of the seropositive haemophiliacs were regular recipients of commercial factor VIII concentrates. Few British intravenous drug abusers sampled in 1984 (2.5% of 203) were positive for anti-HTLV-III. These results show that infection with HTLV-III has rapidly become widespread among homosexuals attending sexually transmitted disease clinics and among haemophiliacs receiving pooled blood products. Thus, while many anti-HTLV-III positive individuals may remain asymptomatic, there may soon be a considerable increase in the incidence of the acquired immune deficiency syndrome and related disease in Britain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985170      PMCID: PMC1418883          DOI: 10.1136/bmj.290.6476.1176

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

1.  Role of sexual and non-sexual practices in the transmission of hepatitis B.

Authors:  K S Lim; V T Wong; K W Fulford; R D Catterall; M Briggs; D S Dane
Journal:  Br J Vener Dis       Date:  1977-06

2.  Levels of neutralizing and binding antibodies to hepatitis-A virus after onset of icterus: a comparison.

Authors:  B Flehmig; J Zahn; A Vallbracht
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

3.  Epidemic hepatitis B with delta-antigenaemia among Dublin drug-abusers.

Authors:  A G Shattock; M G Kelly; J Fielding; Y Arthurs
Journal:  Ir J Med Sci       Date:  1982-11       Impact factor: 1.568

4.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

5.  Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain.

Authors:  R Cheingsong-Popov; R A Weiss; A Dalgleish; R S Tedder; D C Shanson; D J Jeffries; R B Ferns; E M Briggs; I V Weller; S Mitton
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

6.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

7.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS.

Authors:  J E Groopman; S Z Salahuddin; M G Sarngadharan; P D Markham; M Gonda; A Sliski; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Detection of antibody to varicella-zoster virus by competitive and IgM-antibody capture immunoassay.

Authors:  R S Tedder; P P Mortimer; R B Lord
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  8 in total

1.  Monitoring the prevalence of HIV.

Authors:  T E Rohan; T W Meade; P P Mortimer
Journal:  BMJ       Date:  1990-01-06

2.  The acquired immune deficiency syndrome and epidemic of infection with human immunodeficiency virus: costs of care and prevention in an inner London district.

Authors:  A M Johnson; M W Adler; J M Crown
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

3.  Retrovirus infections among patients treated in Britain with various clotting factors.

Authors:  R Cheinsong-Popov; R S Tedder; T O'Connor; S Clayden; A Smith; J Craske; R Weiss
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-19

4.  HIV infection in England and Wales: a changing pattern.

Authors:  H L Taylor; P P Mortimer
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

Review 5.  HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance.

Authors:  S Dougan; B G Evans; N Macdonald; D J Goldberg; O N Gill; K A Fenton; J Elford
Journal:  Epidemiol Infect       Date:  2007-07-30       Impact factor: 2.451

6.  Sexual lifestyle and clinical findings related to HTLV-III/LAV status in homosexual men.

Authors:  B A Evans; S G Dawson; K A McLean; S A Teece; P R Key; R A Bond; K D Macrae; W J Jesson; P P Mortimer
Journal:  Genitourin Med       Date:  1986-12

7.  Prevalence of HIV antibody in high and low risk groups in England. Public Health Laboratory Service Working Group.

Authors: 
Journal:  BMJ       Date:  1989-02-18

Review 8.  Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU).

Authors:  R T D'Aquila; A B Williams
Journal:  Yale J Biol Med       Date:  1987 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.